BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US: AN UPDATED ANALYSIS
    Campbell, D.
    Veenstra, D.
    Migliaccio-Walle, K.
    Dzingina, M.
    Sullivan, S.
    Draica, F.
    Wiemken, T.
    Cha-Silva, A.
    Mugwagwa, T.
    VALUE IN HEALTH, 2024, 27 (06) : S119 - S119
  • [2] Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
    Sandin, Rickard
    Veenstra, David L.
    Vankelegom, Mathilde
    Dzingina, Mendwas
    Sullivan, Sean D.
    Campbell, David
    Ma, Cuiying
    Harrison, Cale
    Draica, Florin
    Wiemken, Timothy Lee
    Mugwagwa, Tendai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (12): : 1290 - 1302
  • [3] Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
    Carlson, Josh
    Foos, Volker
    Kasle, Adam
    Mugwagwa, Tendai
    Draica, Florin
    Wiemken, Timothy Lee
    Nguyen, Jennifer L.
    Cha-Silva, Ashley
    Migliaccio-Walle, Kristen
    Dzingina, Mendy
    VALUE IN HEALTH, 2024, 27 (02) : 164 - 172
  • [4] Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
    Carlos H. Arteaga Duarte
    Michel L. Peters
    Michelle H. M. de Goeij
    Roy Spijkerman
    Maarten J. Postma
    Cost Effectiveness and Resource Allocation, 23 (1)
  • [5] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [6] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
    Lu, Jiayue
    Cai, Hong
    Hao, Yujun
    Lin, Zhang
    Liu, Shang
    Zhan, Yaping
    Ding, Li
    Huang, Meilan
    Li, Zhenyuan
    Xu, Lan
    Yan, Xiujuan
    Yang, Li
    Zhang, He
    Zhang, Wei
    Zhao, Li
    Zhao, Junli
    Wang, Ting
    Gu, Leyi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] In patients with COVID-19 at risk for severe disease, nirmatrelvir plus ritonavir reduced hospitalization or death
    Vassilopoulos, Athanasios
    Mylonakis, Eleftherios
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (06) : JC63 - JC63
  • [8] Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study
    Chen, Xiaohua
    Zhu, Ying
    Shen, Leer
    Zhou, Dan
    Feng, Nannan
    Tong, Qiang
    JOURNAL OF INTENSIVE CARE MEDICINE, 2024, 39 (08) : 742 - 750
  • [9] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
    Butt, Adeel Ajwad
    Yan, Peng
    Shaikh, Obaid S.
    PLOS ONE, 2024, 19 (06):
  • [10] Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
    Hung, Yuan-Pin
    Lee, Jen-Chieh
    Chiu, Chun-Wei
    Lee, Ching-Chi
    Tsai, Pei-Jane
    Hsu, I-Lin
    Ko, Wen-Chien
    ANTIBIOTICS-BASEL, 2022, 11 (02):
12345